-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Small Molecules For Familial Adenomatous Polyposis in Familial Adenomatous Polyposis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Small Molecules For Familial Adenomatous Polyposis in Familial Adenomatous PolyposisDrug Details:Small molecules are under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria) Drug Details: DFV-890 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTX-2735 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VTX-2735 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria) Drug Details: VTX-2735 is under development...
-
Company Insights
New![]()
Innovation and Patenting activity of BAIOO Family Interactive Limited Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of BAIOO Family Interactive Limited Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vutrisiran in Familial Amyloid Cardiomyopathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Vutrisiran in Familial Amyloid Cardiomyopathy Drug Details: Vutrisiran (Amvuttra) is designed to target and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lorpucitinib in Familial Adenomatous Polyposis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Lorpucitinib in Familial Adenomatous Polyposis Drug Details:Lorpucitinib is under development for the treatment of familial adenomatous...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tolcapone in Familial Amyloid Cardiomyopathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tolcapone in Familial Amyloid Cardiomyopathy Drug Details: Tolcapone (CRX-1008) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lerodalcibep in Heterozygous familial hypercholesterolemia (heFH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lerodalcibep in Heterozygous familial hypercholesterolemia (heFH) Drug Details: Lerodalcibep is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) Drug Details: Lerodalcibep is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eplontersen Sodium in Familial Amyloid Neuropathies
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eplontersen Sodium in Familial Amyloid Neuropathies Drug Details: AKCEA-TTR-LRx is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.